Evidence map›Paper›PMID 31371419›Full record

ArticleHaematologica2020

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.

Bing Z Carter, Po Yee Mak, Hong Mu, Xiangmeng Wang, Wenjing Tao, Duncan H Mak, Elisha J Dettman, Michael Cardone, Oleg Zernovak, Takahiko Seki and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Novel targeted therapies in chronic myeloid leukemia.Pharmaceutical science advances · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Pyrazolo[4,3-Molecules (Basel, Switzerland) · 2022
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Bing Z CarterSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bicarter@mdanderson.org mandreef@mdanderson.org.
Po Yee MakSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hong MuSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiangmeng WangSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenjing TaoSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Duncan H MakSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elisha J DettmanEutropics, Cambridge, MA, USA.
Michael CardoneEutropics, Cambridge, MA, USA.
Oleg ZernovakDaiichi Sankyo Co. Ltd., Oncology Laboratories, R&D Division, 2-58, Hiromachi 1-Chrome, Shinagawa-ku, Tokyo, Japan.
Takahiko SekiDaiichi Sankyo Co. Ltd., Oncology Laboratories, R&D Division, 2-58, Hiromachi 1-Chrome, Shinagawa-ku, Tokyo, Japan.
Michael AndreeffSection of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bicarter@mdanderson.org mandreef@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USDaiichi-Sankyo (Japan) · JPEutropics Pharmaceuticals (United States) · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
TOLERANCE INDUCTION BY MEGADOSE STEM CELL TRANSPLANTS IN CML--GVHD AND GVLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ARLINGHAUS, RALPH BERNARD · 1990 to 2014
$41.8M
Commercializing Praedicare Dx TM platform for guiding cancer treatmentsR44CA203610 · NCI · EUTROPICS PHARMACEUTICALS, INC. · PI CARDONE, MICHAEL H · 2017 to 2019
$3.0M
NCI NIH HHS P01 CA049639NCI NIH HHS P30 CA016672NCI NIH HHS R44 CA203610
6 · The paper itself

Abstract

Although highly effective, BCR-ABL1 tyrosine kinase inhibitors do not target chronic myeloid leukemia (CML) stem cells. Most patients relapse upon tyrosine kinase inhibitor therapy cessation. We reported previously that combined BCR-ABL1 and BCL-2 inhibition synergistically targets CML stem/progenitor cells. p53 induces apoptosis mainly by modulating BCL-2 family proteins. Although infrequently mutated in CML, p53 is antagonized by MDM2, which is regulated by BCR-ABL1 signaling. We hypothesized that MDM2 inhibition could sensitize CML cells to tyrosine kinase inhibitors. Using an inducible transgenic Scl-tTa-

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAnimalsCell ProliferationDisease Models, AnimalDrug Resistance, NeoplasmFusion Proteins, bcr-ablMiceNeoplastic Stem CellsProto-Oncogene Proteins c-mdm2Fusion Proteins, bcr-ablProtein Kinase InhibitorsProto-Oncogene Proteins c-mdm2

Identifiers

PMID31371419
PMCPMC7193504
OpenAlexW2966590837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.